Abbott’s colorectal cancer test shows improved sensitivity

Abbott Laboratories showcased enhanced capabilities of its Oncodetect molecular residual disease test for colorectal cancer at the European Society for Medical Oncology Congress. The whole-genome sequencing-based test demonstrated 72.2% sensitivity for detecting colorectal cancer recurrence within two years post-surgery, a significant improvement over its whole-exome sequencing version with just 42.2% sensitivity.

The Beta-CORRECT study analyzed blood samples from 279 primarily stage II and III colorectal cancer patients, taken one month after surgery. The test detects circulating tumor DNA in a single blood draw and has not been cleared or approved by the U.S. Food and Drug Administration.